Indication
Tirzepatide for Weight Loss
Tirzepatide is approved for chronic weight management as Zepbound. In SURMOUNT-1, adults without diabetes lost about 20.9% of body weight on average at 15 mg over 72 weeks, against 3.1% on placebo, with a clear dose-response. SURMOUNT-3 showed it adds substantial further loss even after a successful intensive lifestyle programme.
Key takeaways
- Approved as Zepbound for chronic weight management alongside diet and physical activity.
- SURMOUNT-1: about 20.9% mean reduction at 15 mg over 72 weeks versus 3.1% placebo.
- SURMOUNT-3 showed further substantial loss even after successful intensive lifestyle intervention.
- Results are group means — individual response varies widely around them.
- Maintaining loss generally requires continued treatment (SURMOUNT-4).
| Approved brand | Zepbound |
|---|---|
| Pivotal trial | SURMOUNT-1, N=2,539, 72 weeks |
| Mean reduction at 15 mg | About 20.9% |
| Placebo comparison | About 3.1% |
| Dose-response | Present across 5, 10, and 15 mg |
| After lifestyle intervention | SURMOUNT-3 showed substantial additional loss |
How much weight do people actually lose?
In SURMOUNT-1 the mean was about 20.9% at 15 mg, 19.5% at 10 mg, and 15.0% at 5 mg over 72 weeks, against 3.1% on placebo. Those are averages: a substantial minority lost considerably more, and some lost considerably less. Marketing that presents the headline figure as a typical personal outcome misrepresents how trial means work.
Real-world results are usually smaller, principally because persistence is lower outside a trial that supplies medication free and provides structured follow-up.
Does tirzepatide work if lifestyle change has already worked?
Yes, and SURMOUNT-3 was designed to test exactly that. Every participant first completed a 12-week intensive lifestyle programme and lost at least 5%. Randomised afterwards, 87.5% on tirzepatide achieved a further 5% or greater reduction against 16.5% on placebo.
That result undercuts the common objection that medication is only appropriate for people who have not tried. These participants had, successfully, and still gained substantially more.
How long does it take to see results?
Appetite changes are often noticed within the first weeks, but meaningful weight change accumulates over months because dosing escalates gradually from 2.5 mg. Trial curves continued to fall through week 72 rather than plateauing early, which is why judging the drug after four or eight weeks is premature.
What the evidence shows
- Large mean weight reduction versus placebo at labelled doses over 72 weeks.
- Additional benefit even after a successful intensive lifestyle programme.
- A consistent dose-response across the studied range.
What the evidence does not show
- That an individual will achieve the trial mean.
- That results persist after stopping — SURMOUNT-4 showed the opposite.
- That compounded tirzepatide reproduces these outcomes.
- Trial participants received medication free with structured follow-up, which real-world care rarely matches.
- People with type 2 diabetes lose meaningfully less — see SURMOUNT-2.
- Trials excluded many comorbidities and concurrent medications.
Related: Results and timeline · Weight regain
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
| Series | Wk 0 | Wk 12 | Wk 24 | Wk 40 | Wk 56 | Wk 72 |
|---|---|---|---|---|---|---|
| Tirzepatide 15 mg | 0% | -6.5% | -12.4% | -16.8% | -19.3% | -20.9% |
| Tirzepatide 5 mg | 0% | -5.1% | -9.3% | -12.4% | -14.2% | -15.0% |
| Placebo | 0% | -1.4% | -2.3% | -2.8% | -3.0% | -3.1% |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
Why do real-world results fall short of trial results?
Three factors account for most of the gap, and none of them means the trials were wrong. Trial participants receive medication free, which removes the cost barrier that drives a large share of real-world discontinuation. Trials provide structured follow-up, dietary counselling, and regular contact that routine care rarely matches. And trials enrol people who met eligibility criteria and consented to seventy-two weeks of monitoring, which selects for a more persistent group than the general population.
The practical implication is that a person planning treatment should expect something less than the trial mean and should treat the factors above as levers. Cost planning that assumes years rather than months, and support that approximates the trial's structure, are the two most controllable of them.
What predicts a larger or smaller response?
Presence of type 2 diabetes is the most consistent predictor of a smaller response, documented directly by the difference between SURMOUNT-1 and SURMOUNT-2. Dose reached matters, though the increments diminish above 10 mg. Adherence and persistence matter substantially, and are the factors most affected by cost and tolerability.
Beyond those, much of the variation is unexplained. Two people with similar baseline characteristics on the same dose can reach materially different results, and no currently available test predicts which will be which. This is why trial means should be read as the centre of a wide distribution rather than as a forecast, and why an early assessment of personal response is unreliable.
How should weight change be tracked without distortion?
Weight fluctuates by meaningful amounts day to day for reasons unrelated to fat mass — hydration, sodium, glycogen, bowel content, and hormonal cycles all move the number. Tracking that treats each reading as a signal produces anxiety and, frequently, premature conclusions about whether treatment is working.
The trials measured at fixed intervals over long periods for exactly this reason. Whatever tracking approach a person uses, the useful comparison is between multi-week trends rather than between individual readings, and the interval at which a genuine judgement can be made is months rather than weeks.
What does this page cover, and what does it deliberately leave out?
This page addresses Approved use, trial outcomes, variability and duration and safety, organised around the primary question of tirzepatide for weight loss. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Approved use | Covered on this page | Primary evidence |
| Trial outcomes | Covered on this page | Primary evidence |
| Variability | Covered on this page | Primary evidence |
| Duration and safety | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with a prescriber who knows your history |
What are the limits of what this page can tell you?
Every page on this site rests on a specific clinical evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a prescriber who knows your history.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
Any of the following would change what this page concludes:
- New primary evidence bearing directly on tirzepatide for weight loss.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 4 technical terms this page uses, including adherence, compounded, persistence, placebo — in the specific sense used above.
| adherence | The extent to which a person takes a medicine as prescribed. Real-world adherence to incretin therapy is considerably lower than in trials, which is a principal reason real-world weight outcomes are smaller. |
|---|---|
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| persistence | How long a person continues treatment before stopping altogether. Short persistence is the dominant finding of real-world tirzepatide cohorts. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
Frequently asked questions
How much weight will I lose on tirzepatide?
Trial means were about 20.9% at 15 mg over 72 weeks, but individual results vary widely and real-world averages are typically lower.
How quickly does tirzepatide work?
Appetite changes are often noticed within weeks, but weight change accumulates over months as the dose escalates. Trial curves continued falling through 72 weeks.
Is tirzepatide approved for weight loss?
Yes, as Zepbound for chronic weight management in adults meeting the labelled criteria.
Do I still need to change my diet?
Approved use is alongside diet and physical activity, and SURMOUNT-3 showed the two are additive.
Will the weight come back if I stop?
SURMOUNT-4 found substantial regain after randomised withdrawal.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.